NASDAQ:ADYX - Nasdaq -
3.61
-2.33 (-39.23%)
The current stock price of ADYX is 3.61 null. In the past month the price decreased by -50.75%.
Adynxx Inc. is a clinical-stage biopharmaceutical company. It is focused on therapeutics for the treatment of pain and inflammatory diseases. Adynxx Inc., formerly known as Alliqua BioMedical Inc., is based in San Francisco, United States.
Adynxx Inc.
2150 CABOT BLVD WEST SUITE B
LANGHORNE PA 19047
CEO: David Johnson
Phone: 215-702-8550
The current stock price of ADYX is 3.61 null. The price decreased by -39.23% in the last trading session.
The exchange symbol of Adynxx Inc. is ADYX and it is listed on the Nasdaq exchange.
ADYX stock is listed on the Nasdaq exchange.
Adynxx Inc. (ADYX) has a market capitalization of 3.01M null. This makes ADYX a Nano Cap stock.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ADYX does not pay a dividend.
Adynxx Inc. (ADYX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-38.93).
ChartMill assigns a fundamental rating of 2 / 10 to ADYX. While ADYX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ADYX reported a non-GAAP Earnings per Share(EPS) of -38.93. The EPS decreased by -43.44% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -379.83% | ||
ROA | -83.16% | ||
ROE | -113.96% | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 60% to ADYX. The Buy consensus is the average rating of analysts ratings from 1 analysts.